Conditions

Scarring Alopecia Types and Management: Complete Guide

3,745 words·Compiled from cited medical literature·Not medical advice

TL;DR Summary

Scarring alopecias are permanent hair loss conditions where inflammation destroys hair follicles and replaces them with scar tissue. Classified by the North American Hair Research Society (NAHRS) into lymphocytic (LPP, FFA, CCCA, DLE), neutrophilic (folliculitis decalvans), and mixed types. Trichoscopy showing absent follicular openings is diagnostic with 87% sensitivity. Early treatment with corticosteroids, hydroxychloroquine, or type-specific therapies is critical because destroyed follicles cannot regenerate. Success means stopping progression—not reversing damage. Psychological support is essential as 40% experience depression.

Who This Is For#

This guide is for you if:

• You've been diagnosed with a scarring alopecia (cicatricial alopecia)
• Your scalp biopsy shows fibrosis or follicular destruction
• You have symptoms like itching, burning, or scaling at the hairline margins
• Your dermatologist mentioned LPP, FFA, CCCA, DLE, or folliculitis decalvans
• You see smooth, shiny patches where hair used to grow

This guide is NOT for you if:

• You have temporary hair loss from stress (see telogen effluvium)
• You have pattern hair loss without scalp scarring (see androgenetic alopecia)
• You have patchy hair loss with regrowth potential (see alopecia areata)
• You're experiencing general thinning without inflammation (see diffuse thinning)

What Is Scarring Alopecia?#

Scarring alopecia, also called cicatricial alopecia, describes a group of conditions where inflammation permanently destroys hair follicles. Unlike non-scarring alopecias where follicles remain intact but dormant, scarring alopecias replace follicles with fibrous scar tissue—making regrowth impossible in affected areas.

These conditions represent 3-7% of all hair clinic presentations. While relatively uncommon, their permanent nature makes early diagnosis and treatment critically important.

Why "Scarring" Is Permanent#

The difference between scarring and non-scarring alopecia comes down to whether the follicle's regenerative machinery survives. Every hair follicle contains a "bulge region" housing stem cells that regenerate hair through multiple growth cycles.

In scarring alopecias, inflammation specifically targets and destroys these stem cells. Once the bulge is destroyed and replaced by collagen scar tissue, no force—medical or surgical—can restore that follicle's capacity to produce hair. The body has essentially "sealed over" where the follicle once existed.

This is why you see smooth, shiny scalp in scarring alopecia: the skin no longer has the tiny openings (ostia) where hairs emerge. In non-scarring alopecia, even bald areas retain these openings—evidence that follicles remain, merely dormant.

The NAHRS Classification System#

In 2001, the North American Hair Research Society established a classification system for primary cicatricial alopecias based on the predominant type of inflammatory cell seen on biopsy:

Lymphocytic Scarring Alopecias#

Lymphocyte-predominant inflammation characterizes the most common scarring alopecias:

• Lichen Planopilaris (LPP): Multifocal patches with perifollicular scaling
• Frontal Fibrosing Alopecia (FFA): Band-like recession with eyebrow loss (see FFA guide)
• Central Centrifugal Cicatricial Alopecia (CCCA): Vertex-starting, spreading outward
• Discoid Lupus Erythematosus (DLE): Associated with systemic lupus

Neutrophilic Scarring Alopecias#

Neutrophil-predominant inflammation creates pustular, often painful conditions:

• Folliculitis Decalvans: Pustules with characteristic "tufted" follicles
• Dissecting Cellulitis: Painful nodules and interconnecting sinuses

Mixed Scarring Alopecias#

Both lymphocytes and neutrophils participate:

• Acne Keloidalis Nuchae: Firm papules on posterior neck/scalp
• Erosive Pustular Dermatosis: Rare, often post-surgical or post-radiation

Why Classification Matters for Treatment#

Understanding the inflammatory cell type isn't just academic—it directly guides treatment selection.

Lymphocytic conditions typically respond to immunomodulators like hydroxychloroquine and corticosteroids because these drugs suppress the specific immune pathways driving lymphocyte-mediated attack. Neutrophilic conditions, however, often require antibiotics because bacterial colonization frequently triggers or perpetuates the neutrophilic response.

Treating a neutrophilic condition with hydroxychloroquine alone would likely fail, just as treating lymphocytic LPP with antibiotics alone would miss the target. This is why accurate diagnosis—including biopsy when necessary—is essential before starting treatment.

Lichen Planopilaris (LPP)#

Lichen planopilaris is the classic lymphocytic scarring alopecia, affecting primarily middle-aged women (4:1 female predominance) with peak onset between ages 40-60.

Clinical Presentation#

LPP typically presents as:

• Multiple small patches of hair loss on the vertex and parietal scalp
• Perifollicular erythema (redness around hair follicles) at active margins
• Perifollicular scaling ("tubular casts" around emerging hairs)
• Smooth, shiny, white skin in established patches
• Symptoms of itching, burning, or tenderness in active areas

The Three LPP Variants#

Dermatologists recognize three clinical patterns within the LPP spectrum:

1. Classic LPP: Multifocal irregular patches, typically on vertex
2. Frontal Fibrosing Alopecia (FFA): Band-like frontal and temporal recession with eyebrow/eyelash loss—now more common than classic LPP
3. Graham-Little-Piccardi-Lassueur Syndrome: LPP combined with non-scarring alopecia of armpits/groin plus follicular spiny papules on body

Why LPP Targets Specific Follicle Zones#

LPP inflammation concentrates at the "isthmus"—the middle portion of the follicle where the sebaceous gland attaches. This is not random.

The isthmus represents a unique immunological zone. It lacks the "immune privilege" that protects the lower bulb and contains specialized stem cells crucial for follicle regeneration. When inflammation strikes here, it damages the stem cell population in the bulge (located just above the isthmus).

This explains why LPP causes permanent scarring despite affecting a relatively small zone: it targets the exact region housing the follicle's regenerative capacity.

Central Centrifugal Cicatricial Alopecia (CCCA)#

CCCA is the most common scarring alopecia in women of African descent, affecting an estimated 5.6% of African American women. Despite historical assumptions, we now understand CCCA as a genetic condition—not simply a result of hair care practices.

Clinical Features#

CCCA presents with characteristic features:

• Hair loss beginning at the vertex (crown)
• Centrifugal spread (expanding outward in all directions)
• Gradual thinning progressing to smooth, shiny scalp
• May start with "breakage" and decreased hair density
• Often asymptomatic early; may develop tenderness as progresses

The PADI3 Discovery#

A 2019 New England Journal of Medicine study identified mutations in the PADI3 gene in approximately 25% of CCCA patients. This was groundbreaking.

PADI3 encodes an enzyme essential for proper hair shaft formation. When mutated, it causes structural weakness in the inner root sheath—the protective sleeve around growing hair. This weakness leads to premature shedding of the inner root sheath, which triggers inflammation and eventual follicle destruction.

Reframing CCCA—Genetics, Not Hair Care#

For decades, CCCA was attributed to "traumatic" hair care: hot combs, chemical relaxers, tight braiding. This created stigma and blame directed at patients.

The PADI3 discovery revolutionized understanding. Women with CCCA who have never used chemicals, heat, or tight styles still develop the condition. The genetic defect creates structural vulnerability; hair practices may accelerate progression but do not cause the disease.

This shift matters profoundly for patient counseling. Instead of "you caused this," the message becomes "you have a genetic susceptibility that requires treatment." Yes, reducing mechanical stress is still recommended, but the shame and blame have no place in CCCA management.

Associated Conditions#

CCCA shows striking associations with:

• Uterine fibroids: 5-fold increased risk
• Keloids: 2-fold increased risk
• Type 2 diabetes: Elevated risk (mechanism unclear)

These associations suggest shared genetic or inflammatory pathways worth investigating during CCCA workup.

Discoid Lupus Erythematosus (DLE)#

Discoid lupus represents the intersection of autoimmune disease and scarring alopecia. It can occur as isolated skin disease or as one manifestation of systemic lupus erythematosus (SLE).

Clinical Features#

DLE on the scalp presents with:

• Well-defined erythematous (red) plaques
• Follicular plugging (keratin deposits in follicular openings)
• Central scarring with peripheral activity
• Dyspigmentation (hyperpigmentation at edges, hypopigmentation centrally)
• Scale that, when removed, shows "carpet tack" spikes underneath

Systemic Lupus Connection#

Approximately 10% of patients with isolated DLE eventually develop systemic lupus. Conversely, up to 25% of SLE patients have discoid lesions.

Screening for systemic involvement includes:

• Complete blood count
• Comprehensive metabolic panel
• Antinuclear antibodies (ANA)
• Anti-double-stranded DNA (anti-dsDNA) antibodies
• Urinalysis

DLE Requires Systemic Thinking#

Unlike other scarring alopecias that remain localized to skin, DLE raises the specter of systemic disease. A patient presenting with scalp DLE isn't just losing hair—they may be showing the first sign of lupus affecting kidneys, joints, or blood.

This is why dermatologists approach DLE differently. Treatment addresses both the visible scalp disease (topical and intralesional corticosteroids, antimalarials) and monitors for systemic progression. Laboratory testing and rheumatology referral may be warranted.

The good news: isolated DLE often responds well to treatment, and most patients with skin-only disease never develop systemic lupus. But vigilance is essential.

Neutrophilic Scarring Alopecias#

Folliculitis Decalvans#

Folliculitis decalvans creates some of the most distinctive (and often distressing) appearances in scarring alopecia.

Clinical Features:

• Pustules clustered around follicles
• "Tufted folliculitis": Multiple hairs (5-20) emerging from single dilated follicle
• Crusting and erosions
• Expanding patches of scarring
• Often painful and tender

Pathogenesis: Staphylococcus aureus colonization triggers and perpetuates inflammation, explaining why antibiotics are first-line therapy.

Dissecting Cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens)#

Dissecting cellulitis primarily affects young African American men and creates profound scalp disfigurement.

Clinical Features:

• Deep, fluctuant nodules that interconnect via sinus tracts
• Purulent drainage
• Progressive scarring
• Often associated with acne conglobata and hidradenitis suppurativa (follicular occlusion triad)

Treatment Challenge: This condition is notoriously difficult to treat, often requiring prolonged antibiotic courses, isotretinoin, or biologics like adalimumab.

The Bacterial Connection in Neutrophilic Forms#

Why do some scarring alopecias involve bacteria while others don't? The answer lies in the inflammatory pathway.

In neutrophilic forms, bacteria—particularly Staphylococcus aureus—establish biofilms within follicles. The immune system responds by sending neutrophils, which release enzymes to kill bacteria but also damage surrounding tissue. This creates a destructive cycle: bacteria trigger inflammation, inflammation damages follicles, damaged follicles provide more surface for bacterial attachment.

Breaking this cycle requires addressing both the bacteria (antibiotics) and the inflammation (anti-inflammatory agents). Neither alone typically suffices. This is why folliculitis decalvans often requires combination therapy: rifampicin + clindamycin to address bacterial colonization while suppressing the inflammatory response.

Diagnosis: Trichoscopy and Histopathology#

Accurate diagnosis of scarring alopecia relies on clinical examination, trichoscopy (dermoscopy of the scalp), and often scalp biopsy.

Trichoscopic Findings#

Trichoscopy has transformed scarring alopecia diagnosis, providing a non-invasive window into follicular architecture.

Universal hallmark: Absence of follicular openings (ostia)—the most reliable sign distinguishing scarring from non-scarring alopecia. Studies show 87% sensitivity and 93% specificity.

Type-specific findings:

Scalp Biopsy#

Despite trichoscopy advances, biopsy remains the diagnostic gold standard when:

• Clinical and trichoscopic findings are ambiguous
• Multiple conditions may coexist
• Baseline documentation needed before treatment
• Medicolegal documentation required

Optimal technique: Two 4mm punch biopsies—one from active margin (showing inflammation), one from center (showing end-stage scarring). Both horizontal and vertical sectioning provide maximum diagnostic information.

When Trichoscopy Replaces Biopsy#

The emergence of trichoscopy has changed the diagnostic algorithm for scarring alopecias. Previously, biopsy was nearly universal. Now, many cases can be confidently diagnosed without tissue sampling.

When trichoscopy clearly shows characteristic features—absent ostia plus type-specific signs in a clinically consistent presentation—many dermatologists proceed directly to treatment. Biopsy is reserved for ambiguous cases, suspected overlap syndromes, or when documentation is needed.

This shift benefits patients by avoiding painful procedures and speeding time-to-treatment. However, it requires expertise: subtle findings can be missed, and confident trichoscopic diagnosis demands training and experience.

Treatment Approaches#

Treating scarring alopecia requires understanding three fundamental principles:

1. Early intervention is critical: Every day of active inflammation destroys more follicles
2. The goal is stabilization: Regrowth in scarred areas is not possible
3. Treatment is often long-term: Many patients require indefinite maintenance therapy

First-Line Treatments#

For Lymphocytic Types (LPP, CCCA, DLE):

For FFA specifically: 5-alpha reductase inhibitors (finasteride, dutasteride) show 47-62% stabilization rates (see FFA guide)

For Neutrophilic Types:

Second and Third-Line Options#

When first-line treatments fail:

• Methotrexate: 15-25 mg weekly (lymphocytic types)
• Cyclosporine: 3-5 mg/kg/day (aggressive disease)
• Mycophenolate mofetil: 1-1.5g BID (refractory cases)
• Biologics: Adalimumab for neutrophilic types, under investigation for others

Why Combination Therapy Often Works Best#

Single-agent therapy frequently disappoints in scarring alopecia. Why? Because the disease attacks through multiple pathways simultaneously.

Consider LPP: lymphocytes attack the follicle while the body deposits collagen in response to damage. A corticosteroid might reduce lymphocyte activity, but if another pathway sustains inflammation, the follicle still dies. Adding hydroxychloroquine addresses different immune mechanisms; adding topical therapy attacks inflammation from another angle.

Most experienced dermatologists start with combination approaches for moderate-severe disease: intralesional steroids plus hydroxychloroquine, or corticosteroids plus a second immunomodulator. Monotherapy is often reserved for mild disease or maintenance after stabilization.

Emerging Therapies: JAK Inhibitors#

JAK inhibitors represent the most exciting development in scarring alopecia treatment. Originally developed for rheumatoid arthritis and other autoimmune conditions, these oral medications block Janus kinase pathways central to immune signaling.

Current Evidence#

Pilot studies show promising results:

• Tofacitinib 5mg twice daily: 60% showed reduced inflammation at 6 months
• Baricitinib 4mg daily: Similar efficacy with potentially better safety profile
• Topical ruxolitinib: Under investigation for localized treatment

Limitations and Cautions#

JAK inhibitors are not yet FDA-approved for scarring alopecia. Use is off-label with important considerations:

• Cost: $1,000-5,000 per month without insurance
• Monitoring: Requires regular blood work for safety
• Limitations: Cannot regrow hair in already-scarred areas
• Access: Often requires specialist prescription and prior authorization

JAK Inhibitors—Promise and Perspective#

The enthusiasm for JAK inhibitors in alopecia areata (where they can produce dramatic regrowth) must be tempered for scarring alopecias. In alopecia areata, follicles are attacked but not destroyed—remove the attack, and hair grows back.

In scarring alopecia, follicles are destroyed. JAK inhibitors can reduce active inflammation and prevent further destruction, but they cannot resurrect dead follicles. Their value lies in disease stabilization for treatment-resistant cases, not in restoration.

This distinction matters for patient expectations. A patient who responds to JAK inhibitors might stop losing hair—a significant victory—but won't see regrowth in scarred areas. Success means preservation, not reversal.

Hair Transplantation in Scarring Alopecia#

Hair transplantation presents unique challenges in scarring alopecia that differ fundamentally from transplanting for androgenetic alopecia.

The 2-Year Rule#

Most experts recommend waiting at least 2 years of complete disease inactivity before considering transplantation. Why?

1. Active disease destroys transplants: Transplanted follicles can be attacked just like native ones
2. Disease trajectory unclear: Some alopecias self-stabilize; others relapse unpredictably
3. Investment protection: Transplantation costs $8,000-20,000; losing grafts to disease recurrence wastes resources

Candidate Selection#

Ideal candidates have:

• Documented 2+ years of clinical and trichoscopic inactivity
• Stable, well-controlled disease
• Adequate donor hair density (no donor area involvement)
• Realistic expectations about limited success
• Willingness to continue preventive treatment post-transplant

Outcomes#

Reported outcomes vary widely:

• Success rates: 50-80% (compared to >95% for AGA transplants)
• Complications: Higher risk of keloid formation, especially in CCCA
• Monitoring: Requires close follow-up for early relapse detection

When Transplantation Makes Sense—and When It Doesn't#

Hair transplantation in scarring alopecia is not categorically contraindicated, but it requires careful patient selection and honest counseling.

The patient with FFA who has been stable on hydroxychloroquine for 3 years, has good donor density, and accepts that results may be modest is a reasonable candidate. The patient with actively progressing disease seeking transplantation before trying medical therapy is not.

The key questions: Is the disease truly quiescent? Are expectations realistic? Is continued medical surveillance assured? If all three are yes, transplantation can provide meaningful cosmetic improvement. If any are no, the risk-benefit calculation doesn't favor surgery.

Living with Scarring Alopecia#

Psychological Impact#

Scarring alopecia exacts a psychological toll that often exceeds other hair loss conditions:

• Depression: 40% of patients (vs. 20% in AGA)
• Anxiety: 55% of patients (vs. 30% in AGA)
• Social withdrawal: 60% report avoiding social situations
• Employment impacts: 25% report work-related consequences

The permanence of loss drives much of this distress. Unlike AGA where treatments might restore density, scarring alopecia patients face irreversibility.

Redefining Success in Scarring Alopecia#

Traditional hair loss treatment success means regrowth—more hair than before. This metric fails patients with scarring alopecia, potentially creating despair when treatment "doesn't work."

Reframing success is essential:

• Victory: The disease stops progressing
• Victory: Symptoms (itching, burning) resolve
• Victory: No new patches appear despite active treatment
• Victory: Quality of life improves through symptom control and psychological support

When patients understand that stopping an aggressive, destructive process IS success—even without regrowth—they can engage treatment with realistic hope rather than inevitable disappointment.

Coping Strategies#

Effective approaches include:

Cosmetic Solutions:

• High-quality wigs and hairpieces
• Topical fibers for partial hair loss
• Scalp micropigmentation for camouflage
• Strategic hairstyling to cover affected areas

Psychological Support:

• Support groups (Cicatricial Alopecia Research Foundation provides resources)
• Individual therapy for depression/anxiety
• Online communities for shared experience
• Partner/family education about the condition

Practical Accommodations:

• Sun protection for exposed scalp (increased skin cancer risk)
• Gentle hair care to protect remaining hair
• Regular dermatology follow-up for early relapse detection

When to See a Specialist#

Seek evaluation promptly if you experience:

• Smooth, shiny patches where hair doesn't grow back
• Itching, burning, or tenderness at the hairline
• Pustules or crusting on the scalp
• Loss of eyebrows combined with hairline recession
• Scalp scarring following injury or procedure

Early referral to a dermatologist experienced in hair disorders can prevent substantial permanent loss. The window for intervention is narrow—once follicles scar, the opportunity to save them is gone.

For specialist referrals, consider:

• Academic medical center dermatology departments
• Dermatologists with specific hair loss expertise
• Cicatricial Alopecia Research Foundation physician directory

See our dermatologist guide for finding qualified specialists.

Frequently Asked Questions#

Can scarring alopecia be cured?#

No. Scarring alopecia is a chronic condition requiring ongoing management. Treatment can stop progression and relieve symptoms, but hair that has been lost to scarring cannot be regrown. The goal is preservation—protecting remaining follicles from destruction.

How do I know if my hair loss is scarring or non-scarring?#

Key differences: Scarring alopecia shows smooth, shiny scalp without visible follicular openings. Non-scarring alopecia retains these openings even in bald areas. Trichoscopy (dermoscopy of the scalp) can distinguish with 87% accuracy. Scalp biopsy provides definitive diagnosis.

Is CCCA caused by hair care practices like relaxers or tight braids?#

No. The 2019 discovery of PADI3 gene mutations established CCCA as a genetic condition. While mechanical stress may accelerate progression in genetically susceptible individuals, it does not cause the disease. Many CCCA patients have never used chemicals or tight styles.

How long does treatment take to work?#

Most treatments require 3-6 months to show effect. Dermatologists typically assess response at 3-month intervals using clinical examination and trichoscopy. Treatment is considered successful if the disease stabilizes (no new hair loss) and symptoms improve.

Can I get a hair transplant if I have scarring alopecia?#

Potentially, but only after at least 2 years of complete disease inactivity. Even then, success rates are lower (50-80%) than for non-scarring hair loss, and transplanted follicles can be affected by disease recurrence. Careful candidate selection and realistic expectations are essential.

Are JAK inhibitors a cure for scarring alopecia?#

No. JAK inhibitors can reduce active inflammation and potentially prevent progression in treatment-resistant cases, but they cannot restore hair in already-scarred areas. They are currently used off-label with significant cost and monitoring requirements.

Why did I develop scarring alopecia?#

Most scarring alopecias result from immune system dysfunction targeting hair follicles. Genetic factors play a role (e.g., PADI3 in CCCA). Environmental triggers are suspected in some types (FFA's dramatic rise suggests possible environmental contributors). In many cases, the exact cause remains unknown.

Is scarring alopecia contagious or hereditary?#

Not contagious—you cannot "catch" scarring alopecia from someone. Hereditary patterns vary: CCCA shows family clustering in 15-20% of cases; other types rarely run in families. Genetic susceptibility exists, but direct inheritance is uncommon.

Related Resources#

• Frontal Fibrosing Alopecia: What to Know
• Androgenetic Alopecia: Complete Guide
• Hair Loss Blood Tests Guide
• Finding a Hair Loss Specialist
• Finasteride for Hair Loss